Skip to main content

Change location

You are currently on the Czech Republic (Český) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Czech Republic (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

        • Iomeron 400
      • Medical devices

        • CT Exprès 3D
        • Empower CTA+
    • MRI
      • Contrast agents

        • MultiHance
        • ProHance
        • Vueway
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • Sonovue
    • Nuclear medicine
    • Interventional cardiology
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Events
  • Ceriano Laghetto
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
  1. Home
  2. Our Portfolio
  3. X-ray/CT
  4. Contrast agents

  5. Iomeron
  6. Nefropatie způsobená kontrastní látkou (CIN)

Nefropatie způsobená kontrastní látkou (CIN)

 

1) Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.

 

Thomsen HS, Morcos SK. Eur Radiol. 2009 Apr;19(4):891-7. Epub 2008 Nov 11.

 

View

 

 

2) ESUR guidelines on contrast media.

 

Thomsen HS, Morcos SK; ESUR. Abdom Imaging. 2006 Mar-Apr;31(2):131-40.

 

View

 

 

3) The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.

 

Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L; Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study.Invest Radiol. 2008 Mar;43(3):170-8.

 

View

 

 

4) Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.

 

Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A; Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. Circ Cardiovasc Interv. 2009 Oct;2(5):430-7. Epub 2009 Sep 22.

 

View

Please login to DocCheck
to view our products

Register here Forgot your password?

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Farmakovigilance
  • VPOIS
  • Data Protection

Connect with us

Bracco Imaging Czech s.r.o.
Novodvorská 994 / 138
142 21 Praha 4
Czech Republic
VAT No CZ 24119393
+420 239 044 300

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182